Current structure-based Methods for Designing non-nucleoside Reverse Transcriptase Inhibitors

References

• AIDSInfo . Clinical guidelines. http://aidsinfo.nih.gov
   Google Scholar
• Sebaaly JC , KelleyD. HIV clinical updates: new single-tablet regimens. Ann. Pharmacother., 53(1), 82–94 (2019).
   PubMed Web of Science ®Google Scholar
• Dousson C , AlexandreFR, AmadorAet al. Discovery of the aryl-phospho-indole IDX899, a highly potent anti-HIV non-nucleoside reverse transcriptase inhibitor. J. Med. Chem., 59(5), 1891–1898 (2016).
   PubMed Web of Science ®Google Scholar
• Gray WT , FreyKM, LaskeySBet al. Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance. ACS Med. Chem. Lett., 6(10), 1075–1079 (2015).
   PubMed Web of Science ®Google Scholar
• Yang Y , KangD, NguyenLAet al. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. Elife, 7, e36340 (2018).
   PubMed Web of Science ®Google Scholar
• Chan AH , LeeWG, SpasovKAet al. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: from design to protein crystallography. Proc. Natl Acad. Sci USA, 114(36), 9725–9730 (2017).
   PubMed Web of Science ®Google Scholar
• Namasivayam V , VanangamudiM, KramerVGet al. The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J. Med. Chem., 62(10), 4851–4883 (2019).
   PubMed Web of Science ®Google Scholar
• Seckler JM , BarkleyMD, WintrodePL. Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding. Biophys. J., 100(1), 144–153 (2011).
   PubMed Web of Science ®Google Scholar
• Spence RA , KatiWM, AndersonKS, JohnsonKA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science, 267(5200), 988–993 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson M , KumarP, MolinaJMet al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J. Acquir. Immune Defic. Syndr., 81(4), 463–472 (2019).
   PubMed Web of Science ®Google Scholar
• Orkin C , DejesusE, RamgopalMet al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, Phase 3b, non-inferiority study. Lancet HIV, 4(5), e195–e204 (2017).
   PubMed Web of Science ®Google Scholar
• Permpalung N , PutcharoenO, AvihingsanonA, RuxrungthamK. Treatment of HIV infection with once-daily regimens. Expert Opin. Pharmacother., 13(16), 2301–2317 (2012).
   PubMed Web of Science ®Google Scholar
• Desai M , FieldN, GrantR, McCormackS. Recent advances in pre-exposure prophylaxis for HIV. BMJ, 359, j5011 (2017).
   PubMedGoogle Scholar
• Smerdon SJ , JagerJ, WangJet al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA, 91(9), 3911–3915 (1994).
   PubMed Web of Science ®Google Scholar
• Cote B , BurchJD, Asante-AppiahEet al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett., 24(3), 917–922 (2014).
   PubMed Web of Science ®Google Scholar
• Feng M , WangD, GroblerJA, HazudaDJ, MillerMD, LaiMT. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob. Agents Chemother., 59(1), 590–598 (2015).
   PubMed Web of Science ®Google Scholar
• Basson AE , RheeSY, ParryCMet al. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother., 59(2), 960–971 (2015).
   PubMed Web of Science ®Google Scholar
• Das K , ArnoldE. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol., 3(2), 111–118 (2013).
   PubMedGoogle Scholar
• Das K , ArnoldE. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr. Opin. Virol., 3(2), 119–128 (2013).
   PubMedGoogle Scholar
• Sluis-Cremer N , WainbergMA, SchinaziRF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol., 10(11), 1773–1782 (2015).
   PubMed Web of Science ®Google Scholar
• Ceccherini-Silberstein F , GagoF, SantoroMet al. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J. Virol., 79(16), 10718–10729 (2005).
   PubMed Web of Science ®Google Scholar
• Usach I , MelisV, PerisJE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. Int. AIDS Soc., 16, 1–14 (2013).
   PubMed Web of Science ®Google Scholar
• Medrano J , BarreiroP, TumaPet al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev., 10(2), 110–115 (2008).
   PubMed Web of Science ®Google Scholar
• Apostolova N , FunesHA, Blas-GarciaA, GalindoMJ, AlvarezA, EspluguesJV. Efavirenz and the CNS: what we already know and questions that need to be answered. J. Antimicrob. Chemother., 70(10), 2693–2708 (2015).
   PubMed Web of Science ®Google Scholar
• Decloedt EH , MaartensG. Neuronal toxicity of efavirenz: a systematic review. Expert Opin. Drug Saf., 12(6), 841–846 (2013).
   PubMed Web of Science ®Google Scholar
• Pozniak AL , Morales-RamirezJ, KatabiraEet al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a Phase IIb randomized trial. AIDS, 24(1), 55–65 (2010).
   PubMed Web of Science ®Google Scholar
• Wilkin A , PozniakAL, Morales-RamirezJet al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a Phase IIb randomized trial. AIDS Res. Hum. Retroviruses, 28(5), 437–446 (2012).
   PubMed Web of Science ®Google Scholar
• Giguere P , NheanS, TsengAL, HughesCA, AngelJB. Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications. Can. J. Cardiol., 35(3), 326–340 (2019).
   PubMed Web of Science ®Google Scholar
• Frey KM . Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants. Future Microbiol., 10(11), 1767–1772 (2015).
   PubMed Web of Science ®Google Scholar
• Das K , BaumanJD, ClarkADJret al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl Acad. Sci. USA, 105(5), 1466–1471 (2008).
   PubMed Web of Science ®Google Scholar
• Lansdon EB , BrendzaKM, HungMet al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem., 53(10), 4295–4299 (2010).
   PubMed Web of Science ®Google Scholar
• Gong Z , XieZ, QiuJ, WangG. Synthesis, biological evaluation and molecular docking study of 2-substituted-4,6-diarylpyrimidines as alpha-glucosidase inhibitors. Molecules, 22(11), 1865 (2017).
   PubMed Web of Science ®Google Scholar
• Huang B , KangD, YangJ, ZhanP, LiuX. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin. Ther. Pat., 26(2), 281–289 (2016).
   PubMed Web of Science ®Google Scholar
• Jin K , YinH, DeClercq E, PannecouqueC, MengG, ChenF. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. Eur. J. Med. Chem., 145, 726–734 (2018).
   PubMed Web of Science ®Google Scholar
• Xue P , LuHH, ZhuYYet al. Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors. Bioorg. Med. Chem. Lett., 27(8), 1640–1643 (2017).
   PubMed Web of Science ®Google Scholar
• Simon P , BaszczynskiO, SamanDet al. Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1. Eur. J. Med. Chem., 122, 185–195 (2016).
   PubMed Web of Science ®Google Scholar
• Bollini M , DomaoalRA, ThakurVVet al. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J. Med. Chem., 54(24), 8582–8591 (2011).
   PubMed Web of Science ®Google Scholar
• Frey KM , BolliniM, MislakACet al. Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. J. Am. Chem. Soc., 134(48), 19501–19503 (2012).
   PubMed Web of Science ®Google Scholar
• Frey KM , PuleoDE, SpasovKA, BolliniM, JorgensenWL, AndersonKS. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J. Med. Chem., 58(6), 2737–2745 (2015).
   PubMed Web of Science ®Google Scholar
• Lee WG , Gallardo-MaciasR, FreyKMet al. Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group. J. Am. Chem. Soc., 135(44), 16705–16713 (2013).
   PubMed Web of Science ®Google Scholar
• Asahchop EL , OliveiraM, WainbergMAet al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob. Agents Chemother., 55(2), 600–607 (2011).
   PubMed Web of Science ®Google Scholar
• Singh K , MarchandB, RaiDKet al. Biochemical mechanism of HIV-1 resistance to rilpivirine. J. Biol. Chem., 287(45), 38110–38123 (2012).
   PubMed Web of Science ®Google Scholar
• Kang D , FangZ, LiZet al. Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J. Med. Chem., 59(17), 7991–8007 (2016).
   PubMed Web of Science ®Google Scholar
• Kang D , FangZ, HuangBet al. Structure-based optimization of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants. J. Med. Chem., 60(10), 4424–4443 (2017).
   PubMed Web of Science ®Google Scholar
• Huang B , ChenW, ZhaoTet al. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against wild-type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J. Med. Chem., 62(4), 2083–2098 (2019).
   PubMed Web of Science ®Google Scholar
• Kang D , ZhangH, WangZet al. Identification of Dihydrofuro[3,4- d]pyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties. J. Med. Chem., 62(3), 1484–1501 (2019).
   PubMed Web of Science ®Google Scholar
• Aly YL , PedersenEB, LaColla P, LoddoR. Synthesis and anti-HIV-1 activity of new MKC-442 analogues with an alkynyl-substituted 6-benzyl group. Arch. Pharm. (Weinheim), 340(5), 225–235 (2007).
   PubMed Web of Science ®Google Scholar
• Petersen L , JessenCH, PedersenEB, NielsenC. Synthesis and evaluation of new potential HIV-1 non-nucleoside reverse transcriptase inhibitors. New analogues of MKC-442 containing Michael acceptors in the C-6 position. Org. Biomol. Chem., 1(20), 3541–3545 (2003).
   PubMed Web of Science ®Google Scholar
• Azeem SM , MuwongeAN, ThakkarN, LamKW, FreyKM. Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors. J. Mol. Graph. Model., 79, 133–139 (2018).
   PubMed Web of Science ®Google Scholar